Moving towards Mainstream: Paying attention to Psychedelics



Earlier this year, the DEA significantly increased production quotas for certain psychedelic drugs to support late-stage clinical trials for conditions like PTSD and treatment resistant depression. Such drugs include psilocybin, MDMA, LSD and DMT. 

This is not just a policy update but rather a signal that psychedelic assisted treatments may soon become part of everyday psychiatric care.  

What many people fail to realize is that these substances are still Schedule 1, meaning that there are complex compliance rules, strict federal oversight and real legal exposure for the organizations using them. 

As innovation accelerates, so do certain risks. These risks include informed consent challenges, regulatory scrutiny, protocol deviations, documentation gaps, and liability concerns. 

Helping healthcare teams translate clinical practice into defensible, compliant care through policy review, risk mitigation and case analysis can be an essential safeguard for those who have incorporated such treatments into standard practice of care routines.  

When new treatments emerge, the ability to protect patients and the ability to protect organizations must happen simultaneously. 

For attorneys and their clients, these changes can carry important legal and practical ramifications.

Where emerging mental health therapies are concerned, how is your organization preparing for the compliance and liability side? 

Source: Law 360 | Chew | Kimberly | Ramped Up Psychedelic Production Carries Opportunity Risk, 2026